ZTEK
ZentekZTEK
ZTEK
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
44% more capital invested
Capital invested by funds: $1.11M [Q3] → $1.6M (+$492K) [Q4]
13% more funds holding
Funds holding: 15 [Q3] → 17 (+2) [Q4]
0.17% more ownership
Funds ownership: 1.46% [Q3] → 1.64% (+0.17%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for ZTEK.
Financial journalist opinion
Based on 3 articles about ZTEK published over the past 30 days
Neutral
Accesswire
1 week ago
Zentek Announces Results of Canada Revenue Agency Audit
GUELPH, ON / ACCESS Newswire / March 21, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), announces that the Canada Revenue Agency ("CRA") has completed an audit (the "Audit") on January 14, 2025 of the Company's 2018 and 2019 renunciation of Canadian exploration expenses ("CEE") in favour of subscribers of the private placements of flow-through common shares which closed on December 21, 2018 and December 20, 2019 (the "Flow-Through Financings") for aggregate gross proceeds of $4,210,000.
Neutral
Accesswire
2 weeks ago
Zentek Completes Shelf-Life Efficacy Testing for ZenGUARD(TM) Enhanced Air Filter Commercialization
GUELPH, ON / ACCESS Newswire / March 12, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company announces that shelf-life efficacy testing has been completed on aged ZenGUARD™ Enhanced Air Filters, which is required for medical device compliance.
Neutral
Newsfile Corp
4 weeks ago
Zentek Announces US$30 Million At-The-Market Offering in the United States
Guelph, Ontario--(Newsfile Corp. - March 3, 2025) - Zentek Ltd. (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company"), an intellectual property technology development and commercialization company is pleased to announce it has entered into an at-the-market offering agreement (the "ATM Agreement"), dated as of today pursuant to which the Company proposes to issue and sell such number of common shares in the capital of the Company (the "Common Shares") as would result in aggregate gross proceeds to the Company of up to US$30 million (the "Offering").
Neutral
Accesswire
1 month ago
Zentek Subsidiary Albany Graphite Corp. Provides Update on Thermal Purification Testwork Results
GUELPH, ON / ACCESS Newswire / February 14, 2025 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased to announce, further to its press release dated January 8, 2025, that its wholly owned subsidiary, Albany Graphite Corp. ("AGC") has received additional results from the fluidized bed reactor ("FBR") testwork.
Neutral
Accesswire
2 months ago
Zentek Provides Update on ZenGUARD(TM) Enhanced Air Filters for the Canadian Market
GUELPH, ON / ACCESS Newswire / January 17, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide an update on the launch of ZenGUARD™ Enhanced Air Filters in the Canadian Market.
Neutral
Accesswire
2 months ago
Zentek Subsidiary Albany Graphite Corp. Simplifies Process to Achieve Five Nines Purity
GUELPH, ON / ACCESSWIRE / January 8, 2025 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased to announce that its wholly owned subsidiary, Albany Graphite Corporation (AGC) has achieved a preliminary five-nines purity of 99.9991% directly from a larger Albany graphite deposit flotation concentrate sample utilizing an operational pilot-scale fluidized bed reactor (FBR).
Neutral
Accesswire
3 months ago
Zentek Provides Update on International Opportunities
GUELPH, ON / ACCESSWIRE / December 12, 2024 / Zentek Ltd. (" Zentek "or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, has signed a Memorandum of Understanding ("MOU") with Al-Ramez International Group - through Saudi Excellence Holding Company - establishing a strategic partnership to drive innovation and commercialization in advanced technologies across the Kingdom of Saudi Arabia ("KSA") and the Middle East and North Africa ("MENA") region on November 14 th 2024.
Neutral
Accesswire
3 months ago
Zentek Ltd. Regains Nasdaq Compliance re Minimum Bid Price
GUELPH, ON / ACCESSWIRE / December 9, 2024 / Zentek Ltd. ("Zentek"or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, announces that on December 3, 2024, it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock ("Common Stock") has been above US $1.00 per share for the last 11 consecutive business days.
Neutral
Accesswire
4 months ago
ZenGUARD(TM) Enhanced Air Filters to Be Added as Class 1 Medical Device Under Zentek's Medical Device Establishment Licence
GUELPH, ON / ACCESSWIRE / November 27, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, announces its decision that its ZenGUARD™ Enhanced Air Filters will be added under the company's existing medical device establishment licence ("MDEL"), similar to ZenGUARD™ Surgical Masks.
Neutral
Accesswire
4 months ago
Zentek and Triera Biosciences Ltd. Receive $1.1 Million Government of Canada Contract to Test Multivalent Aptamer Technology
GUELPH, ON / ACCESSWIRE / November 6, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd.
Charts implemented using Lightweight Charts™